Effect of Pam3Cys induced protection on the therapeutic efficacy of miltefosine against experimental visceral leishmaniasis.

Abstract

Prophylactic potential of synthetic bacterial lipopeptide and a TLR2 agonist, Pam3Cys was first evaluated against experimental visceral leishmaniasis in rodent model. After establishing the potential its effect on therapeutic efficacy of miltefosine was also studied. Pam3Cys showed 74.64% inhibition in parasitic establishment when administered by ip route at a dose of 100 μg/animal spaced at two weeks, i.e. on day -7 and +7 of challenge with Leishmania donovani amastigotes. However, when aforesaid dose of Pam3Cys was given with sub-curative dose of miltefosine (2.5 mg/kg for 5 days) its efficacy enhanced from 49.80% to 92.25%. These findings revealed that this lipopeptide has potential protective efficacy which significantly enhanced the therapeutic efficacy of miltefosine used at low dose against Leishmania infection and warrants detailed investigations on its possible immunopotentiatory actions.

• Authors: Nishi Shakya, Shraddha A Sane, Shagun Shankar, Suman Gupta
• Journal: Peptides (Peptides) Vol. 32 Issue 10 Pg. 2131-3 (Oct 2011) ISSN: 1873-5169 [Electronic] United States
• PMID: 21959258 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Antiprotozoal Agents
• Lipoproteins
• Phosphorylcholine
• miltefosine
• 2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine
• Cysteine

Topics

• Animals
• Antiprotozoal Agents (therapeutic use)
• Cricetinae
• Cysteine (analogs & derivatives, therapeutic use)
• Female
• Leishmaniasis, Visceral (drug therapy, prevention & control)
• Lipoproteins (therapeutic use)
• Male
• Mice
• Mice, Inbred BALB C
• Phosphorylcholine (analogs & derivatives, therapeutic use)